Studies of primary central nervous system lymphoma with fluorine-18- fluorodeoxyglucose positron emission tomography

S. S. Rosenfeld, J. M. Hoffman, R. E. Coleman, M. J. Glantz, M. W. Hanson, S. C. Schold

Research output: Contribution to journalArticle

94 Scopus citations

Abstract

Primary CNS lymphoma is a rare and highly malignant primary brain tumor. Ten patients with biopsy-proven primary CNS lymphoma were studied with 18F- 2-fluoro-2-deoxy-D-glucose (FDG) and positron emission tomography (PET) to demonstrate the findings in patients with this tumor. The accumulation of FDG in primary CNS lymphoma is similar to that seen in anaplastic gliomas and is significantly more prominent than in low grade astrocytomas (p = 0.001). Steroid therapy substantially reduced the amount of FDG uptake in the one case studied both before and after its administration. The difference in FDG uptake between steroid-treated and untreated cases of primary CNS lymphoma, however, did not reach statistical significance (p = 0.40). Primary CNS lymphoma, like gliomas, suppresses the metabolism of both contiguous and distant but functionally linked areas of the brain. This study thus shows that the metabolic behavior of primary CNS lymphoma, as monitored by FDG-PET, resembles that of malignant glial tumors.

Original languageEnglish (US)
Pages (from-to)532-536
Number of pages5
JournalJournal of Nuclear Medicine
Volume33
Issue number4
StatePublished - Jan 1 1992

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Studies of primary central nervous system lymphoma with fluorine-18- fluorodeoxyglucose positron emission tomography'. Together they form a unique fingerprint.

  • Cite this

    Rosenfeld, S. S., Hoffman, J. M., Coleman, R. E., Glantz, M. J., Hanson, M. W., & Schold, S. C. (1992). Studies of primary central nervous system lymphoma with fluorine-18- fluorodeoxyglucose positron emission tomography. Journal of Nuclear Medicine, 33(4), 532-536.